PERSONIFITsIROVANNYY PODKhOD K OPREDELENIYu I INTERPRETATsII PROSTATSPETsIFIChESKOGO ANTIGENA V KROVI

M N Peshkov

doi:10.17816/MAJ12435-37

Medical academic journal ›› 2012, Vol. 12 ›› Issue (4) : 35 -37. DOI: 10.17816/MAJ12435-37

Articles

research-article

PERSONIFITsIROVANNYY PODKhOD K OPREDELENIYu I INTERPRETATsII PROSTATSPETsIFIChESKOGO ANTIGENA V KROVI

M N Peshkov

Author information +

History +

PDF

Abstract

Cite this article

Download citation ▾

M N Peshkov. PERSONIFITsIROVANNYY PODKhOD K OPREDELENIYu I INTERPRETATsII PROSTATSPETsIFIChESKOGO ANTIGENA V KROVI. Medical academic journal, 2012, 12(4): 35-37 DOI:10.17816/MAJ12435-37

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность) / Под ред. В. И. Чиссова и др.- М., 2010.

[2]	Catalona W. J., Partin A. W., Slawin K. M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective m ulticenter clinical trial // JAMA.- 1998.- Vol. 279, № 1542.

[3]	Catalona W. J., Smith D. S., Ratliff T. L. et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening // JAMA.- 1993.- Vol. 270.- Р. 948.

[4]	Cheville J. C., Karnes R. J., Therneau T. M. et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy // J. of Clinical Oncology.- 2008.- Vol. 26, № 24.- Р. 3930-3936.

[5]	Jemal A., Bray F., Center M. M. et al. Global cancer statistics // CA Cancer Journal for Clinicians.- 2011.- Vol. 61, № 2.- Р. 69-90.

[6]	Koh C. M., Bieberich C. J., Dang C. V. et al. // MYC and prostate cancer, Genes and Cancer.- 2010.- Vol. 1, № 6.- Р. 617-628.

[7]	Stamey T. A., Caldwell M., McNeal J. E. et al. The PSA era in the United States is over for prostate cancer: what happened in the past 20 Years? // J. Urol.- 2004.

[8]	Schaefer A., Jung M., Mollenkopf H. J. et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma // International Journal of Cancer.- 2010.- Vol. 126, № 5.- Р. 1166-1176.

[9]	Schroder F. H., Rooboletal M. J. et al. Screening and prostate cancer mortality in a randomized european study // New Engl. J. Med.- 2009.-Vol. 360, № 13.- Р. 1320-1328.

[10]	Stephenson A. J., Scardino P. T., Eastham J. A. et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy // Journal of the National Cancer Institute.- 2006.- Vol. 98, № 10.- Р. 715-717.

[11]	Thompson I. M., Ankerst D. P., Chi C. et al. // Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial // J. Natl Cancer Inst - 2006.- Vol. 98.- Р. 529-534.

[12]	Wing M.C., Valenzuela L.A., Murphy G.P., et al. // Purification of a human prostate specific antigen // Invest. Urol.- 1979.- Vol. 17.- Р. 159.

[13]	Zheng S.L., Sun J., Wiklund F., et al. // Cumulative association of five genetic variants with prostate cancer // N. Engl. J. Med.- 2008.- Vol. 358.- Р. 910.